Trial Outcomes & Findings for Anterior Pituitary Hormone Replacement in Traumatic Brain Injury (NCT NCT00957671)

NCT ID: NCT00957671

Last Updated: 2018-06-29

Results Overview

Maximum Oxygen Uptake was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

15 participants

Primary outcome timeframe

baseline

Results posted on

2018-06-29

Participant Flow

Subjects with a history of mild to severe traumatic brain injury were recruited from 2010 to 2014. Subjects were screened for abnormal growth hormone secretion by glucagon stimulation test. 19 subjects were screened for this study. 15 of the subjects met final inclusion/exclusion criteria and began the treatment phase.

Participant milestones

Participant milestones
Measure
Human Growth Hormone
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Overall Study
STARTED
15
Overall Study
COMPLETED
15
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Anterior Pituitary Hormone Replacement in Traumatic Brain Injury

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Human Growth Hormone
n=15 Participants
Recombinant human growth hormone (rhGH) self administered daily for one year Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total)
Age, Categorical
<=18 years
0 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
15 Participants
n=99 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
Age, Continuous
45.5 years
STANDARD_DEVIATION 11.2 • n=99 Participants
Sex: Female, Male
Female
5 Participants
n=99 Participants
Sex: Female, Male
Male
10 Participants
n=99 Participants
Region of Enrollment
United States
15 Participants
n=99 Participants
Age at time of injury
34.3 years
STANDARD_DEVIATION 15.7 • n=99 Participants

PRIMARY outcome

Timeframe: baseline

Maximum Oxygen Uptake was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Maximum Oxygen Uptake at Baseline.
29.0 mL/kg/min
Standard Deviation 7.2

PRIMARY outcome

Timeframe: one year

Maximum Oxygen Uptake was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Maximum Oxygen Uptake After One Year of Human Growth Hormone Replacement Therapy.
32.1 mL/kg/min
Standard Deviation 7.4

PRIMARY outcome

Timeframe: baseline

Minute ventilation was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Minute Ventilation at Baseline.
90.4 L/minute
Standard Deviation 24.2

PRIMARY outcome

Timeframe: one year

Minute ventilation was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Minute Ventilation After One Year of Human Growth Hormone Replacement Therapy.
102.4 L/minute
Standard Deviation 23.1

PRIMARY outcome

Timeframe: baseline

Respiratory exchange ratio was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Respiratory Exchange Ratio at Baseline.
1.27 ratio of CO2/O2
Standard Deviation 0.12

PRIMARY outcome

Timeframe: one year

Respiratory exchange ratio was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Respiratory Exchange Ratio After One Year of Human Growth Hormone Replacement Therapy.
1.27 ratio of CO2/O2
Standard Deviation 0.10

PRIMARY outcome

Timeframe: baseline

Oxygen Pulse was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart. Oxygen pulse is calculated by dividing VO2 consumed (mL/min) by heart rate (beats/min) yielding mL/beat. This provides an estimate of cardiac stroke volume.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Oxygen Pulse at Baseline.
15.2 mL/beat
Standard Deviation 4.1

PRIMARY outcome

Timeframe: one year

Oxygen Pulse was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart. Oxygen pulse is calculated by dividing VO2 consumed (mL/min) by heart rate (beats/min) yielding mL/beat. This provides an estimate of cardiac stroke volume.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Oxygen Pulse After One Year of Human Growth Hormone Replacement Therapy.
16.4 mL/beat
Standard Deviation 4.2

SECONDARY outcome

Timeframe: baseline

The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Total recall is a sum of all word list items correctly recalled immediately on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest). A higher score indicates a better outcome.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Neuropsychological Function as Measured by California Verbal Learning Test-II With Total Recall at Baseline.
45.7 scores on a scale
Standard Deviation 10.8

SECONDARY outcome

Timeframe: One year

The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Total recall is a sum of all word list items correctly recalled immediately on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest). A higher score indicates a better outcome.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Neuropsychological Function as Measured by California Verbal Learning Test-II With Total Recall After 1 Year of Human Growth Hormone Replacement Therapy.
51.0 scores on a scale
Standard Deviation 9.4

SECONDARY outcome

Timeframe: baseline

The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Delayed recall is a sum of all word list items correctly recalled after a 25 minute delay on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest). A higher score indicates a better outcome.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Neuropsychological Function as Measured by California Verbal Learning Test-II With Delayed Recall at Baseline.
9.9 scores on a scale
Standard Deviation 3.8

SECONDARY outcome

Timeframe: One year

The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Delayed recall is a sum of all word list items correctly recalled after a 25 minute delay on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest). A higher score indicates a better outcome.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Neuropsychological Function as Measured by California Verbal Learning Test-II With Delayed Recall After 1 Year of Human Growth Hormone Replacement Therapy.
11.2 scores on a scale
Standard Deviation 2.6

SECONDARY outcome

Timeframe: baseline

The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. Total recall is a measure of the subjects memory immediately after viewing the stimulus page. Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest). A higher score indicates a better outcome.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Total Recall at Baseline
18.7 scores on a scale
Standard Deviation 5.7

SECONDARY outcome

Timeframe: one year

The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. Total recall is a measure of the subjects memory immediately after viewing the stimulus page. Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest). A higher score indicates a better outcome.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Total Recall After 1 Year of Human Growth Hormone Replacement Therapy.
22.7 scores on a scale
Standard Deviation 5.1

SECONDARY outcome

Timeframe: baseline

The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. The delayed recall is a measure of the subjects memory after a 25 minutes delay. The participants are asked to freely recall and again draw the six figures.Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest). A higher score indicates a better outcome.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Delayed Recall at Baseline
7.2 scores on a scale
Standard Deviation 2.9

SECONDARY outcome

Timeframe: one year

The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. The delayed recall is a measure of the subjects memory after a 25 minutes delay. The participants are asked to freely recall and again draw the six figures.Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest). A higher score indicates a better outcome.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Delayed Recall After 1 Year of Human Growth Hormone Replacement Therapy
9.1 scores on a scale
Standard Deviation 2.2

SECONDARY outcome

Timeframe: baseline

Digit Span; Wechsler Memory Scale III (WMS III). Digits Forward is a test of digit span (range = 3 to 9 digits) consisting of seven items (each with 2 trials). Digits Backward is a test of digit span (range = 3 to 9 digits); however the participant must provide the presented sequence in reverse order. The test consists of seven items (each with 2 trials). Total score is calculated by adding the scores from forward and backward. Data is reported as raw scores. Score ranges are 0 (lowest) to 32 (highest). A higher score indicates a better outcome.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Neuropsychological Function as Measured by Digit Span Total at Baseline
16.0 scores on a scale
Standard Deviation 4.5

SECONDARY outcome

Timeframe: one year

Digit Span; Wechsler Memory Scale III (WMS III). Digits Forward is a test of digit span (range = 3 to 9 digits) consisting of seven items (each with 2 trials). Digits Backward is a test of digit span (range = 3 to 9 digits); however the participant must provide the presented sequence in reverse order. The test consists of seven items (each with 2 trials). Total score is calculated by adding the scores from forward and backward. Data is reported as raw scores. Score ranges are 0 (lowest) to 32 (highest). A higher score indicates a better outcome.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Neuropsychological Function as Measured by Digit Span Total After One Year of Human Growth Hormone Replacement Therapy.
17.0 scores on a scale
Standard Deviation 3.9

SECONDARY outcome

Timeframe: baseline

Processing Speed Index is a subcategory of the Wechsler Adult Intelligence Scale III (WAIS-III). Processing speed refers to the speed of cognitive processes and response output. This index is comprised of performances on two separate tests of visuomotor speed of information processing ability. On one test (Coding) participants refer to a key on top of a page to translate non-verbal symbols to an alpha-numeric digit. The participants then fill in boxes with the correct symbol assigned to a particular number. On the other test (Symbol Search) participants are asked to visually scan and mark items that are identical to one of two targets. If neither target is shown in the array the participant must mark out the work "NO". Total correct responses for both task within 120 seconds are recorded. Ranges are 0 (lowest) to 150 (highest) with 100 being the normal average. A higher score indicates a better outcome.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Neuropsychological Function as Measured by Processing Speed Index at Baseline
102.3 scores on a scale
Standard Deviation 14.9

SECONDARY outcome

Timeframe: one year

Processing Speed Index is a subcategory of the Wechsler Adult Intelligence Scale III (WAIS-III). Processing speed refers to the speed of cognitive processes and response output. This index is comprised of performances on two separate tests of visuomotor speed of information processing ability. On one test (Coding) participants refer to a key on top of a page to translate non-verbal symbols to an alpha-numeric digit. The participants then fill in boxes with the correct symbol assigned to a particular number. On the other test (Symbol Search) participants are asked to visually scan and mark items that are identical to one of two targets. If neither target is shown in the array the participant must mark out the work "NO". Total correct responses for both task within 120 seconds are recorded. Ranges are 0 (lowest) to 150 (highest) with 100 being the normal average. A higher score indicates a better outcome.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Neuropsychological Function as Measured by Processing Speed Index After One Year of Human Growth Hormone Replacement Therapy.
106.6 scores on a scale
Standard Deviation 15.0

SECONDARY outcome

Timeframe: baseline

Letter Fluency is a condition measured as part of the subcategory, Verbal Fluency, in the Delis-Kaplan Executive Function System (D-KEFS). Subjects are asked to name as many words as they can starting with a specified letter for 60 seconds. The words can not be names, places, numbers or grammatical variants of previous answers. Repeated answers are not scored as a correct response. There are 3 trials, with 3 different letters. The total number of correct responses is totaled for all 3 trials and a Letter Fluency Score is given. A higher score is considered better. There is no set range as the score depends on how many correct words the subject relays in the given time period.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Neuropsychological Function as Measured by Letter Fluency at Baseline
38.5 scores on a scale
Standard Deviation 14.5

SECONDARY outcome

Timeframe: one year

Letter Fluency is a condition measured as part of the subcategory, Verbal Fluency, in the Delis-Kaplan Executive Function System (D-KEFS). Subjects are asked to name as many words as they can starting with a specified letter for 60 seconds. The words can not be names, places, numbers or grammatical variants of previous answers. Repeated answers are not scored as a correct response. There are 3 trials, with 3 different letters. The total number of correct responses is totaled for all 3 trials and a Letter Fluency Score is given. A higher score is considered better. There is no set range as the score depends on how many correct words the subject relays in the given time period.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Neuropsychological Function as Measured by Letter Fluency After One Year of Human Growth Hormone Replacement Therapy
35.4 scores on a scale
Standard Deviation 13.0

SECONDARY outcome

Timeframe: baseline

Beck Depression Inventory (BDI-II) is used to measure the severity of depression symptoms. The BDI-II contains 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs are: 0-13: minimal depression; 14-19: mild; depression; 20-28: moderate depression; 29-63: severe depression.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Depression as Measured by the Beck Depression Inventory at Baseline.
13.8 scores on a scale
Standard Deviation 9.7

SECONDARY outcome

Timeframe: one year

Beck Depression Inventory (BDI-II) is used to measure the severity of depression symptoms. The BDI-II contains 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs are: 0-13: minimal depression; 14-19: mild; depression; 20-28: moderate depression; 29-63: severe depression.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Depression as Measured by Beck Depression Inventory After One Year of Human Growth Hormone Replacement Therapy.
6.2 scores on a scale
Standard Deviation 6.9

SECONDARY outcome

Timeframe: baseline

Fatigue Severity Scale (FSS) is a measure of fatigue and how that fatigue interferes with life. It is a 9-item scale, with a range from 9 to 63, with a higher number indicating greater severity.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Fatigue as Measured Using Fatigue Severity Scale at Baseline.
44.3 scores on a scale
Standard Deviation 13.5

SECONDARY outcome

Timeframe: one year

Fatigue Severity Scale (FSS) is a measure of fatigue and how that fatigue interferes with life. It is a 9-item scale, with a range from 9 to 63, with a higher number indicating greater severity.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Fatigue Measured Using the Fatigue Severity Scale After One Year of Human Growth Hormone Therapy.
34.0 scores on a scale
Standard Deviation 12.5

SECONDARY outcome

Timeframe: baseline

Population: This is the data for the 10 male subjects enrolled in this study.

Maximum torque production during isometric contraction of the knee extensor muscles.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=10 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Muscle Function in Male Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 at Baseline.
206.0 Newton-Meters
Standard Deviation 32.41

SECONDARY outcome

Timeframe: one year

Population: This is the data for the 10 male subjects in this study.

Maximum torque production during isometric contraction of the knee extensor muscles.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=10 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Muscle Function in Male Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy.
209.6 Newton-Meters
Standard Deviation 37.65

SECONDARY outcome

Timeframe: baseline

Population: This data is for the 10 male subjects enrolled in this study.

Maximum torque production during maximal isokinetic contractions at 90 degrees per second.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=10 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Muscle Function in Male Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 at Baseline.
175.2 Newton-Meters
Standard Deviation 36.61

SECONDARY outcome

Timeframe: one year

Population: This data is for the 10 male subjects in this study.

Maximum torque production during maximal isokinetic contractions at 90 degrees per second.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=10 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Muscle Function in Male Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy.
182.6 Newton-Meters
Standard Deviation 45.29

SECONDARY outcome

Timeframe: baseline

Muscle fatigue is measured using repetitive isokinetic contractions of the knee extensors at 90 degrees per second. Each subject was asked to produce 40 contractions at full force. Data is presented as % of maximum torque at the 40th contraction in the fatigue protocol.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Muscle Fatigue as Measured by Biodex Pro 4 at Baseline.
35.1 Percent of Maximum Torque
Standard Deviation 6.30

SECONDARY outcome

Timeframe: one year

Muscle fatigue is measured using repetitive isokinetic contractions of the knee extensors at 90 degrees per second. Each subject was asked to produce 40 contractions at full force. Data is presented as % of maximum torque at the 40th contraction in the fatigue protocol.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Muscle Fatigue as Measured by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy.
36.9 Percent of Maximum Torque
Standard Deviation 9.89

SECONDARY outcome

Timeframe: baseline

Population: This data is for the 10 male subjects in the study.

Body mass was calculated from whole body scan taken using a GE Lunar iDEXA.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=10 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.
96.04 kilograms
Standard Deviation 18.38

SECONDARY outcome

Timeframe: one year

Population: This is the data for the 10 male subjects in the study.

Body mass was calculated from whole body scan taken using a GE Lunar iDEXA

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=10 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.
96.55 kilograms
Standard Deviation 19.67

SECONDARY outcome

Timeframe: baseline

Population: This data is for the 10 male subjects enrolled in this study.

Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=10 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Lean Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline
61.68 kilograms
Standard Deviation 7.55

SECONDARY outcome

Timeframe: one year

Population: This data is for the 10 male subjects enrolled in the study.

Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=10 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Lean Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.
63.70 kilograms
Standard Deviation 8.14

SECONDARY outcome

Timeframe: baseline

Population: This data is for the 10 male subjects enrolled in this study.

Fat free mass is calculated from whole body scan measured using a GE Lunar iDEXA.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=10 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Fat Free Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.
31.19 kilograms
Standard Deviation 13.75

SECONDARY outcome

Timeframe: one year

Population: This is the data for the 10 male subjects enrolled in the study.

Fat free mass is calculated from whole body scan measured on a GE Lunar iDEXA.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=10 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Fat Free Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.
29.67 kilogram
Standard Deviation 14.30

SECONDARY outcome

Timeframe: baseline

Population: This data is for the 10 male subjects enrolled in this study.

Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=10 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Percent Body Fat as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.
32.47 percent of body fat
Standard Deviation 8.47

SECONDARY outcome

Timeframe: one year

Population: This data is for the 10 male subjects in the study.

Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=10 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Percent Body Fat in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.
30.5 percent of body fat
Standard Deviation 9.40

SECONDARY outcome

Timeframe: baseline

Population: This data is for the 5 female subjects enrolled in this study.

Maximum torque production during isometric contraction of the knee extensor muscles.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=5 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Muscle Function in Female Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 at Baseline.
131.5 Newton-Meters
Standard Deviation 26.38

SECONDARY outcome

Timeframe: one year

Population: This data is for the 5 female subjects in the study.

Maximum torque production during isometric contraction of the knee extensor muscles.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=5 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Muscle Function in Female Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy
130.7 Newton-Meters
Standard Deviation 34.77

SECONDARY outcome

Timeframe: baseline

Population: This data is for the 5 female subjects enrolled in this study.

Maximum torque production during maximal isokinetic contractions at 90 degrees per second.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=5 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Muscle Function in Female Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 at Baseline
103.9 Newton-Meters
Standard Deviation 12.56

SECONDARY outcome

Timeframe: one year

Population: This data is for the 5 female subjects enrolled in this study.

Maximum torque production during maximal isokinetic contractions at 90 degrees per second.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=5 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Muscle Function in Female Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy
99.6 Newton-Meters
Standard Deviation 17.58

SECONDARY outcome

Timeframe: baseline

Perceptual fatigue was measured before and directly after performing the muscle fatigue exercise protocol (40 continuous maximal force isokinetic knee extensions at 90 degress per second). Subjects were asked to rate their fatigue on a scale of 0-10 with 0 being no fatigue at all and 10 being extreme fatigue. Data is presented as change in fatigue rating induced by exercise testing.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Perceptual Fatigability as Measured by a Fatigue Rating Scale at Baseline.
3.78 units on a scale
Standard Deviation 1.75

SECONDARY outcome

Timeframe: one year

Perceptual fatigue was measured before and directly after performing the muscle fatigue exercise protocol (40 continuous maximal force isokinetic knee extensions at 90 degress per second). Subjects were asked to rate their fatigue on a scale of 0-10 with 0 being no fatigue at all and 10 being extreme fatigue. Data is presented as change in fatigue rating induced by exercise testing.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=15 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Perceptual Fatigability as Measured by a Fatigue Rating Scale After One Year of Human Growth Hormone Therapy.
3.17 units on a scale
Standard Deviation 1.54

SECONDARY outcome

Timeframe: baseline

Population: This is the data for the 5 females in the study.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=5 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.
75.64 kilograms
Standard Deviation 10.80

SECONDARY outcome

Timeframe: one year

Population: This data represents the 5 females in the study.

Body mass was calculated from whole body scan taken using a GE Lunar iDEXA

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=5 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy
76.54 kilograms
Standard Deviation 10.57

SECONDARY outcome

Timeframe: baseline

Population: This data is for the 5 female subjects in the study.

Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=5 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Lean Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline
43.84 kilograms
Standard Deviation 1.42

SECONDARY outcome

Timeframe: one year

Population: This data is for the 5 female subjects in the study.

Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=5 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Lean Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.
44.92 kilograms
Standard Deviation 3.47

SECONDARY outcome

Timeframe: baseline

Population: This data is for the 5 female subjects in the study.

Fat free mass is calculated from whole body scan measured using a GE Lunar iDEXA.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=5 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Fat Free Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.
29.31 kilograms
Standard Deviation 9.86

SECONDARY outcome

Timeframe: one year

Population: This is the data for the 5 female subjects.

Fat free mass is calculated from whole body scan measured on a GE Lunar iDEXA.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=5 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Fat Free Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy
29.15 kilograms
Standard Deviation 8.74

SECONDARY outcome

Timeframe: baseline

Population: This data is for the 5 female subjects enrolled in the study.

Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=5 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Percent Body Fat in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.
38.92 percent of body fat
Standard Deviation 8.17

SECONDARY outcome

Timeframe: one year

Population: This data is for the 5 female subjects enrolled in this study.

Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.

Outcome measures

Outcome measures
Measure
Human Growth Hormone
n=5 Participants
recombinant human growth hormone (rhGH) self administered daily for one year. Human Growth Hormone: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total).
Percent Body Fat in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.
38.74 percent of body fat
Standard Deviation 6.84

Adverse Events

Human Growth Hormone

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Randall Urban, MD

University of Texas Medical Branch

Phone: 409-772-1176

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place